These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38160916)

  • 1. Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial.
    Neylon J; Ma TM; Savjani R; Low DA; Steinberg ML; Lamb JM; Nickols NG; Kishan AU; Cao M
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1181-1191. PubMed ID: 38160916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
    Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
    BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seminal vesicle intrafraction motion during the delivery of radiotherapy sessions on a 1.5 T MR-Linac.
    Muinck Keizer DM; Willigenburg T; der Voort van Zyp JRN; Raaymakers BW; Lagendijk JJW; Boer JCJ
    Radiother Oncol; 2021 Sep; 162():162-169. PubMed ID: 34293410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis.
    Pham J; Neilsen BK; Liu H; Cao M; Yang Y; Sheng K; Ma TM; Kishan AU; Ruan D
    Med Phys; 2024 Jan; 51(1):612-621. PubMed ID: 38055353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
    BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First 500 Fractions Delivered with a Magnetic Resonance-guided Radiotherapy System: Initial Experience.
    Sahin B; Zoto Mustafayev T; Gungor G; Aydin G; Yapici B; Atalar B; Ozyar E
    Cureus; 2019 Dec; 11(12):e6457. PubMed ID: 32025388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of intrafractional prostate motion and its dosimetric impact in MRI-guided online adaptive radiotherapy with gating.
    Xiong Y; Rabe M; Nierer L; Kawula M; Corradini S; Belka C; Riboldi M; Landry G; Kurz C
    Strahlenther Onkol; 2023 Jun; 199(6):544-553. PubMed ID: 36151215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soft-tissue prostate intrafraction motion tracking in 3D cine-MR for MR-guided radiotherapy.
    de Muinck Keizer DM; Kerkmeijer LGW; Maspero M; Andreychenko A; van der Voort van Zyp JRN; van den Berg CAT; Raaymakers BW; Lagendijk JJW; de Boer JCJ
    Phys Med Biol; 2019 Dec; 64(23):235008. PubMed ID: 31698351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5T MR-Linac.
    de Muinck Keizer DM; Kerkmeijer LGW; Willigenburg T; van Lier ALHMW; Hartogh MDD; van der Voort van Zyp JRN; de Groot-van Breugel EN; Raaymakers BW; Lagendijk JJW; de Boer JCJ
    Radiother Oncol; 2020 Oct; 151():88-94. PubMed ID: 32622779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 stereotactic prostate ablative radiotherapy with KIM (SPARK) trial.
    Hewson EA; Nguyen DT; O'Brien R; Poulsen PR; Booth JT; Greer P; Eade T; Kneebone A; Hruby G; Moodie T; Hayden AJ; Turner SL; Hardcastle N; Siva S; Tai KH; Martin J; Keall PJ
    Radiother Oncol; 2020 Oct; 151():234-241. PubMed ID: 32828839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DMLC tracking and gating can improve dose coverage for prostate VMAT.
    Colvill E; Poulsen PR; Booth JT; O'Brien RT; Ng JA; Keall PJ
    Med Phys; 2014 Sep; 41(9):091705. PubMed ID: 25186380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electromagnetic Transmitter-Based Prostate Gating for Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy: An Evaluation of Intrafraction Motion.
    De Bari B; Guibert G; Slimani S; Bashar Y; Risse T; Guisolan N; Trouillot J; Abel J; Weber P
    Curr Oncol; 2024 Feb; 31(2):962-974. PubMed ID: 38392066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.
    Kishan AU; Ma TM; Lamb JM; Casado M; Wilhalme H; Low DA; Sheng K; Sharma S; Nickols NG; Pham J; Yang Y; Gao Y; Neylon J; Basehart V; Cao M; Steinberg ML
    JAMA Oncol; 2023 Mar; 9(3):365-373. PubMed ID: 36633877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrafraction Motion Management of Renal Cell Carcinoma With Magnetic Resonance Imaging-Guided Stereotactic Body Radiation Therapy.
    Prins FM; Stemkens B; Kerkmeijer LGW; Barendrecht MM; de Boer HJ; Vonken EPA; Lagendijk JJW; Tijssen RHN
    Pract Radiat Oncol; 2019 Jan; 9(1):e55-e61. PubMed ID: 30261329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy.
    Cuccia F; Mazzola R; Nicosia L; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Vitale C; Mantoan B; De Simone A; Sicignano G; Ruggieri R; Cavalleri S; Alongi F
    Radiat Oncol; 2020 Jul; 15(1):178. PubMed ID: 32698843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
    Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-fraction prostate stereotactic body radiotherapy: Dose reconstruction with electromagnetic intrafraction motion tracking.
    Jaccard M; Ehrbar S; Miralbell R; Hagen T; Koutsouvelis N; Poulsen P; Rouzaud M; Tanadini-Lang S; Tsoutsou P; Guckenberger M; Zilli T
    Radiother Oncol; 2021 Mar; 156():145-152. PubMed ID: 33310011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fiducial marker based intra-fraction motion assessment on cine-MR for MR-linac treatment of prostate cancer.
    de Muinck Keizer DM; Pathmanathan AU; Andreychenko A; Kerkmeijer LGW; van der Voort van Zyp JRN; Tree AC; van den Berg CAT; de Boer JCJ
    Phys Med Biol; 2019 Apr; 64(7):07NT02. PubMed ID: 30794995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate SBRT With Intrafraction Motion Management Using a Novel Linear Accelerator-Based MV-kV Imaging Method.
    Gorovets D; Burleson S; Jacobs L; Ravindranath B; Tierney K; Kollmeier M; McBride S; Happersett L; Hunt M; Zelefsky M
    Pract Radiat Oncol; 2020; 10(5):e388-e396. PubMed ID: 32454176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gating has a negligible impact on dose delivered in MRI-guided online adaptive radiotherapy of prostate cancer.
    Wahlstedt I; Andratschke N; Behrens CP; Ehrbar S; Gabryś HS; Schüler HG; Guckenberger M; Smith AG; Tanadini-Lang S; Tascón-Vidarte JD; Vogelius IR; van Timmeren JE
    Radiother Oncol; 2022 May; 170():205-212. PubMed ID: 35351536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.